Humana Inc (HUM)

Rating: SELL

Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.

Investment Thesis

The bull case — 'Bull — Margin Recovery / Re-Rate' (8% weight) — targets $386, -3% vs spot. It needs Gross Margin to surprise to the upside.

The dashboard below is the whole argument on one page: spot ($397) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The structural case — 'Structural — Medicare/Medicaid Reform / MLR Squeeze' (20%) — targets $96, -76% vs spot. This sits below the 52-week low — a genuine structural impairment, not a mild pullback.

Key Debate

Gross Margin explains 90% of Monte Carlo outcome variance — the single variable that decides which side is right.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q1): management +0.29 vs analyst floor +0.00 → delta +0.29 (n=25 mgmt / 13 Q&A; 32th pctile across the S&P book, z -0.6).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 1000 articles): avg ticker sentiment +0.12 (bullish 19% / bearish 7%)

Scenario Analysis

The tree runs from a structural 'Structural — Medicare/Medicaid Reform / MLR Squeeze' downside ($96) to a 'Bull — Margin Recovery / Re-Rate' bull case ($386); the probability-weighted blend (PWEV $218) is -45% versus spot.

Scenario rationale — what each probability buys (the driver path behind every target):

• Structural — Medicare/Medicaid Reform / MLR Squeeze (20%, $96). Structural impairment — Medicare/Medicaid reform / MLR squeeze: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 96.1; probability: 0.2.
• Cost-Trend Spike / Rate Inadequacy (17%, $163). Cyclical downturn — membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy weakens for 1–2 years before normalising. Drivers — implied_target: 163.19; probability: 0.17.
• Base — Membership + Premium Growth (35%, $227). Mid-cycle — normalised membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy; disciplined capital allocation; steady returns. Drivers — implied_target: 226.65; probability: 0.35.
• Growth — MA / Care-Services (Optum-style) (20%, $306). Upside — MA + care-services growth lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 305.98; probability: 0.2.
• Bull — Margin Recovery / Re-Rate (8%, $386). Upside tail — sustained tight conditions or a structural re-rate on MA + care-services growth. Drivers — implied_target: 386.44; probability: 0.08.

Valuation Triangulation

Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.

Monte Carlo — the distribution, not a point

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $190 and 19% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (90% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 20x terminal FCF multiple → $265. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median forward multiple (P/E 18.285x) implies $166. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.

Across all anchors the spread is wide (genuine disagreement — low valuation confidence).

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Health Payers Providers

This name sits in the Health Payers Providers as a managed_care. membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: UNH (managed_care) · CVS (managed_care) · HCA (providers) · ELV (managed_care) · CI (managed_care) · HUM (managed_care) · CNC (managed_care) · DVA (providers) · UHS (providers)

On the cluster's key downside — Cost-Trend Spike / Reimbursement-Reform Squeeze () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The health_payers_providers cycle is the shared macro driver. Driver — medical-cost trend (MLR) + utilization + reimbursement/regulation Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 2% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $9B + PV(terminal) $32B = EV $41B; + net cash → equity $32B ÷ diluted shares 0.12B = $265/share (exit-multiple terminal).

• Gordon (perpetuity-growth) terminal at 2.5% → $226/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 3% vs WACC 8% → below WACC — the incremental build is value-dilutive.

Peer set

Peer-median fwd P/E → $166; EV/Rev → $1,948.

Weighted fair-value math

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Managed Care / Health Services multiple (AI re-rating) (base 24x)

Load-Bearing Assumptions

DCF: WACC 8%, terminal multiple 20×, FY+5 revenue $185B. Triangulation leans 41% on DCF, 29% on PWEV.

Reasons the Thesis Could Fail (Falsifiable)

P(>current)=18.6% below 30% band — bear weighting or opex may be too severe; verify. A miss on Gross Margin drops the case toward the structural target $96.

Fact / Inference / Speculation

• FACT: Spot $397; 52-week range $162–$380; engine rating SELL; base-case target $218 (-45%).
• INFERENCE: Triangulated FV $226 (-43%). Gross Margin explains 90% of Monte Carlo outcome variance — the single variable that decides which side is right.
• SPECULATION: At current prices the embedded bet is that Gross Margin surprises to the upside — Gross Margin carries 90% of outcome variance.

Recommendation: SELL

Defensive: rating SELL; triangulated fair value $226 (-43% vs spot) — the risk/reward is skewed to the downside on Gross Margin. The debate is Gross Margin (90% of variance) — a fundamental call. SBC runs —M TTM (disclosed in the appendix).